Inactive Instrument

MaxCyte, Inc. Stock London S.E.

Equities

MXCN

USU575801258

Advanced Medical Equipment & Technology

Sales 2024 * 36.42M Sales 2025 * 46.63M Capitalization 504M
Net income 2024 * -48M Net income 2025 * -45M EV / Sales 2024 * 9.73 x
Net cash position 2024 * 150M Net cash position 2025 * 120M EV / Sales 2025 * 8.23 x
P/E ratio 2024 *
-10.6 x
P/E ratio 2025 *
-11.4 x
Employees 143
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.77%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 49 -
Director of Finance/CFO 54 23-03-26
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 67 22-11-30
Director/Board Member 71 06-04-30
Director/Board Member 68 04-02-29
More insiders
MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes four instruments, which are known as the ATx, STx, GTx and VLx, as well as a portfolio of proprietary related disposables and consumables.
Related indices
More about the company